Longevity play TMRW raises $7m seed round from Tidal and inks TruDiagnostic deal
The longevity platform founded by former iflix CEO Mark Britt has closed its first VC round — backed, in large part, by its own members
Your cells have an age, and it is not the same as your birthday. Working that out has become a booming industry.
While blood diagnostics have become the bread and butter of a thousand new health platforms, most will hand you a PDF with 30 data points and call it done. TMRW CEO Mark Britt is building on 1,700.
TMRW has raised approximately $7 million in seed funding to expand its clinical footprint and refine the patient experience, moving beyond digital-only health tools to a proactive clinical environment.
The round was led by Sydney-based Tidal Ventures, with participation from Melbourne fund Capital Zed and a cohort of high-net-worth entrepreneurs and family offices — the majority of whom are active TMRW members themselves.
